(Circulation. 2005;111:1094-1096.)
© 2005 American Heart Association, Inc.
Editorial |
From the Dipartimento Malattie Cardiovascolari, Hospital R. Silvestrini, Perugia, Italy.
Correspondence to Paolo Verdecchia, MD, Dipartimento Malattie Cardiovascolari, Ospedale R. Silvestrini, Località S. Andrea delle Fratte, 06100 Perugia, Italy. E-mail verdec{at}tin.it
Key Words: Editorials hypertension blood pressure epidemiology
| Introduction |
|---|
|
|
|---|
See p 1121
| Different Hypertension Subtypes |
|---|
|
|
|---|
Although ISH is an important determinant of cardiovascular risk, possibly because it reflects diffuse atherosclerotic processes, IDH does not seem to be a condition of increased risk,5,912 perhaps because it might be a sign of a general paucity of atherosclerosis. The quite benign nature of IDH is further corroborated by the generally good response of elevated diastolic BP to antihypertensive treatment. According to the Third National Health and Nutrition Examination Survey (NHANES), treatment of hypertension normalizes diastolic BP (<90 mm Hg) in 89.7% of subjects, whereas it succeeds in normalizing systolic BP (<140 mm Hg) in only 49.0% of subjects.13 Similar results have been obtained from analysis of major intervention trials, which showed a greater degree of diastolic than systolic BP control. For example, in the Hypertension Optimal Treatment (HOT) study,14 more than 90% of subjects achieved diastolic BP normalization, whereas fewer than 50% achieved systolic BP normalization. In the Antihypertensive and Lipid-Lowering Trial to Prevent Heart Attack (ALLHAT)15 and the Controlled Onset Verapamil Investigation of Cardiovascular Events (CONVINCE)16 trials, approximately 90% of participants had their diastolic BP normalized after 2 years of treatment, whereas approximately 50% achieved systolic BP normalization. In treated hypertensive subjects, those with uncontrolled systolic BP were at greater risk of cardiovascular disease than those with uncontrolled diastolic BP after adjustment for confounding factors.17 Thus, effective systolic BP control is the real challenge and the main focus of treatment.
Because of the clear pathophysiological and clinical dissimilarities between the hypertension subtypes outlined above, a more precise knowledge of their natural history and clinical predictors may help to define and implement early, specific, and individualized prevention strategies.
In this issue of Circulation, Franklin and colleagues18 from the Framingham Heart Study report on the results of their categorization of hypertension subtypes in 3915 untreated participants who were free of previous cardiovascular events at the biennial examination carried out in the years 1953 to 1957. Subjects were followed up for 10 years up to biennial examination 9, performed in the years 1965 to 1967. The subjects who started an antihypertensive treatment during follow-up, as well as those with a new cardiovascular event, were censored at the corresponding dates. Thus, the Framingham investigators had the unique opportunity to track the natural history of the distinct hypertension subtypes over the long term, in the absence of the confounding effect of antihypertensive treatment and prior cardiovascular events.
The most interesting finding of the study is the following: compared with subjects with optimal BP (<120/80 mm Hg) at entry and after adjustment for several confounders, those with IDH were extremely more likely (ie, 23.1 times more likely) to develop SDH at follow-up. Furthermore, subjects with normal or high-normal BP at entry were 3.32 and 7.96 times more likely, respectively, than those with optimal BP to develop SDH at follow-up. Normal and high-normal BP at entry were also significant predictors of ISH at follow-up, with adjusted odds ratios of 3.26 and 4.82 compared with the subjects belonging to the optimal BP group. SDH at entry also increased the likelihood of developing ISH at follow-up, with a significant adjusted odds ratio of 1.69. Such evolution had been previously reported as "burned-out" diastolic hypertension19 and associated with weight loss and continued cigarette smoking over time.19 The figure shows the adjusted hazard ratios for the different hypertension subtypes at the follow-up visit according to the different BP categories at the baseline visit, with the optimal BP group as reference (Figure).
|
| Significance of Isolated Diastolic Hypertension |
|---|
|
|
|---|
Because the final visit in this study was carried out in the years 1965 to 1967, the modern clinical implications of these findings must take into account the current availability of potent and well-tolerated antihypertensive drugs. Implications may be subtle and double edged: The relatively easy control of IDH with current antihypertensive drugs, if not accompanied by an adequate control of other risk factors for atherosclerosis through appropriate health-promoting lifestyle modifications and pharmacological measures when needed, might ultimately fail to retard the progression of vascular lesions, with consequent possible evolution toward progressive arterial stiffening and superimposed systolic hypertension in the long run. Thus, the subjects with IDH, although possibly not at increased risk in the short or middle term,5,912 should be carefully monitored over time. In these patients, the goal of treatment should be the control of all cardiovascular risk factors, not solely the BP normalization.
One finding in the present report that is not easy to explain is the high likelihood of subjects with ISH at baseline to develop SDH at follow-up, with an adjusted odds ratio of 7.10 compared with the subjects with optimal BP at entry.18 The mean age of these subjects at entry was 54.4 years. These data suggest that a progressive rise in peripheral arteriolar resistance can occur over time even in middle-aged subjects with ISH, despite being, as a group, at the top of the age-diastolic BP relation.2 A large stroke volume might have been the driving mechanism of ISH in these subjects, with later superimposition of increased peripheral resistance possibly paralleled by a rise in central artery stiffness.
| Significance of Prehypertension |
|---|
|
|
|---|
These data provide further support to the argument that prehypertension, intended as the combination of normal plus high-normal BP categories, is a useful working definition in the setting of cardiovascular disease prevention because it identifies individuals at increased risk of developing progressive vasculopathy with stiffening of the aorta and elastic arteries over time. One should not forget that, because of the continuous nature of the relationship between BP and cardiovascular disease, most BP-associated cardiovascular complications occur in individuals with prehypertension. In a previous analysis of the Framingham Heart Study, compared with the subjects with optimal BP, those with high-normal BP showed a significantly increased risk of cardiovascular disease independent of other risk factors, and a nonsignificant trend toward an increased incidence of events was also noted in the group with normal BP.21 According to the Joint National Committee VII recommendations,20 the subjects with prehypertension are not necessarily candidates for drug therapy. Rather, they should be rechecked in 1 year20 and firmly advised to practice effective lifestyle modification22 to reduce their risk of developing future hypertension and associated cardiovascular disease.
| Acknowledgments |
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
2. Franklin SS. New interpretation of blood pressure: the importance of pulse pressure. In: Oparil S and Weber MA, eds. Hypertension: A Companion to Brenner and Rectors The Kidney. St Louis, Mo: W.B. Saunders; 2000: 227234.
3. Smulyan H, Safar ME. Systolic blood pressure revisited. J Am Coll Cardiol. 1997; 29: 14071413.[Abstract]
4. ORourke MF. Arterial Function in Health and Disease. Edinburgh, UK: Churchill Livingston; 1982.
5. Fang J, Mafhavan S, Cohen H, Alderman MH. Isolated diastolic hypertension: a favourable finding among young and middle-aged hypertensive subjects. Hypertension. 1995; 26: 377382.
6. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 19882000. JAMA. 2003; 290: 199206.
7. Franklin SS, Gustin W IV, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997; 96: 308315.
8. Witteman JC, Grobbee DE, Valkenburg HA, van Hemert AM, Stijnen T, Burger H, Hofman A. J-shaped relation between change in diastolic blood pressure and progression of aortic atherosclerosis. Lancet. 1994; 343: 504507.[CrossRef][Medline] [Order article via Infotrieve]
9. Pickering TG. Isolated diastolic hypertension. J Clin Hypertens. 2003; 5: 411413.
10. Nielsen WB, Lindenstrom E, Vestbo J, Jensen GB. Is diastolic hypertension an independent risk factor for stroke in the presence of normal systolic blood pressure in the middle-aged and elderly? Am J Hypertens. 1997; 10: 634639.[CrossRef][Medline] [Order article via Infotrieve]
11. Petrovitch H, Curb JD, Bloom-Marcus E. Isolated systolic hypertension and risk of stroke in Japanese-American men. Stroke. 1995; 26: 2529.
12. Strandberg TE, Saloman VV, Vanhanen HT, Pitkala K, Miettinen TA. Isolated diastolic hypertension, pulse pressure, and mean arterial pressure as predictors of mortality during a follow-up of up to 32 years. J Hypertens. 2002; 20: 399404.[CrossRef][Medline] [Order article via Infotrieve]
13. Lloyd-Jones DM, Evans JC, Larson M, ODonnel CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension. 2000; 36: 594599.
14. Hansson L, Zanchetti A, Carruthers G, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn CH, Wedel H, Westerling S, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351: 17551762.[CrossRef][Medline] [Order article via Infotrieve]
15. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 29812897.
16. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ, CONVINCE Research Group. Principal results of the Controlled ONset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. JAMA. 2003; 289: 20732082.
17. Benetos A, Bean TK, Gaurier S, Smulyan H, Guize L. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Intern Med. 2002; 102: 577581.
18. Franklin SS, Pio JR, Wong ND, Larson MG, Leip EP, Vasan RS, Levy D. Predictors of new-onset diastolic and systolic hypertension: the Framingham Heart Study. Circulation. 2005; 111: 11211127.
19. Bulpitt CJ, Palmer AJ, Fletcher AE, Bradley IC, Broxton JS, Davis AJ, Ganvir PL, Gostick NK, Mayhew SR, Mukerji D. Proportion of patients with isolated systolic hypertension who have burned-out diastolic hypertension. J Hum Hypertens. 1995; 9: 675678.[Medline] [Order article via Infotrieve]
20. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ, and the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003; 42: 12061252.
21. Vasan RS, Larson MG, Leip EP, Evans JC, ODonnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001; 345: 12911297.
22. Thomas RJ, Kottke TE, Brekke MJ, Brekke LN, Brandel CL, Aase LA, DeBoer SW. Attempts at changing dietary and exercise habits to reduce risk of cardiovascular disease: whos doing what in the community? Prev Cardiol. 2002; 5: 102108.[Medline] [Order article via Infotrieve]
Related Article:
Circulation 2005 111: 1121-1127.
This article has been cited by other articles:
![]() |
J. A. Chirinos, S. S. Franklin, R. R. Townsend, and L. Raij Body Mass Index and Hypertension Hemodynamic Subtypes in the Adult US Population Arch Intern Med, March 23, 2009; 169(6): 580 - 586. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. N. Kelly, D. Gu, J. Chen, J.-f. Huang, J.-c. Chen, X. Duan, X. Wu, C. L. Yau, P. K. Whelton, and J. He Hypertension Subtype and Risk of Cardiovascular Disease in Chinese Adults Circulation, October 7, 2008; 118(15): 1558 - 1566. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Aronson, M. L. Fontes, Y. Miao, D. T. Mangano, and for the Investigators of the Multicenter Study of Risk Index for Perioperative Renal Dysfunction/Failure: Critical Dependence on Pulse Pressure Hypertension Circulation, February 13, 2007; 115(6): 733 - 742. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |